Filter News

Sosei Announces Key Appointments Of Head Of Investor Relations And Corporate Communications And Group Financial Controller

Published: Sep 19, 2017

TOKYO--(BUSINESS WIRE)--Sosei Group Corporation (‘Sosei’; TSE Mothers Index 4565), an
international biopharmaceutical company originating from Japan, today
announces the appointment of Chris Cargill as Head of Investor Relations
and Corporate Communications and Kieran Johnson as the company’s Group
Financial Controller.

Mr. Cargill joins Sosei from J.P. Morgan, where he was a Vice President
in the U.K. Healthcare Investment Banking and Corporate Broking Group
and focused on the life sciences industry, including the pharmaceutical
and biotechnology sectors. Mr. Cargill brings a wealth of experience
across corporate broking, investor relations, capital markets, and
strategic advisory. He began his career in the Corporate Finance M&A
division of KPMG, and holds double bachelor’s degrees in law and
business (banking & finance), and a Diploma in Languages (Japanese) from
Monash University in Melbourne, Australia.

Mr. Johnson was most recently Financial Controller for GlaxoSmithKline’s
UK pharmaceuticals sales and marketing division. Over the course of his
25-plus year career, he has gained diverse international experience in
financial reporting, financial compliance and M&A, and in addition
worked on the creation of ViiV Healthcare, GSK’s HIV joint venture with
Pfizer. Mr. Johnson commenced his accounting career at KPMG, where he
spent 10 years on diversified financial and due diligence assignments
specializing in pharmaceutical companies. He is a Fellow of the
Institute of Chartered Accountants in England and Wales and holds a
Bachelor of Science (Hons) from the University of Bath in the U.K.

Commenting on the appointments, Peter Bains, CEO at Sosei, said: “I am
delighted to welcome Chris and Kieran to the team as we continue to
build Sosei into a global biopharmaceutical presence. Chris’ industry
perspectives and experience will be crucial as we move forward with our
strategic business initiatives and build our international profile.
Similarly, Kieran’s global financial controls experience will enable him
to play a key role leading initiatives that support our growth
ambitions. I look forward to working with both Chris and Kieran in their
new roles.”

About Sosei

Sosei Group Corporation is an international biopharmaceutical company
originating from Japan that discovers and develops innovative
biopharmaceuticals for the treatment of Alzheimer's disease,
schizophrenia, cancer, migraine, addiction, metabolic disease, and other
indications. By utilizing its GPCR structure-based drug design platform
technology, Sosei has established a product pipeline with first/best in
class potential. Through development and commercialization partnerships,
Sosei has already delivered two bronchodilators for COPD which generate
significant and stable revenue streams that enable further growth. Sosei
partners include Novartis, Allergan, AstraZeneca, MedImmune, MorphoSys,
Teva, and Pfizer and we are actively looking for new partnerships to
enhance the development of our products and help us deliver them to
patients worldwide.

This press release contains forward-looking statements, including
statements about the discovery, development and commercialisation of
products. Various risks may cause Sosei’s actual results to differ
materially from those expressed or implied by the forward-looking
statements, including: adverse results in clinical development
programmes; failure to obtain patent protection for inventions;
commercial limitations imposed by patents owned or controlled by third
parties; dependence upon strategic alliance partners to develop and
commercialise products and services; difficulties or delays in obtaining
regulatory approvals to market products and services resulting from
development efforts; the requirement for substantial funding to conduct
research and development and to expand commercialisation activities; and
product initiatives by competitors. As a result of these factors,
prospective investors are cautioned not to rely on any forward-looking
statements. We disclaim any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information,
future events or otherwise.